{
    "clinical_study": {
        "@rank": "70488", 
        "arm_group": {
            "arm_group_label": "mFOLFOX6", 
            "arm_group_type": "Experimental", 
            "description": "Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6."
        }, 
        "brief_summary": {
            "textblock": "The role of perioperative chemotherapy in potentially operable advanced gastric cancer (AGC)\n      with regional lymph node metastasis is still in the area of controversy. The aim of this\n      study is to evaluate the efficacy and toxicity of folinic acid (FA), infusional\n      5-fluorouracil (5-FU), and oxaliplatin (modified FOLFOX6) in potentially resectable AGC with\n      regional lymph node (LN) metastasis."
        }, 
        "brief_title": "A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer", 
        "condition": "Advanced Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously untreated patients with pathologically proven advanced gastric\n             adenocarcinoma with regional LN metastasis (clinical stage: cT2-4 and N+)\n\n          -  At least one measurable regional lymph node metastasis according to the Response\n             Evaluation Criteria in Solid Tumors (RECIST v. 1.0)\n\n          -  age between 18 and 75 years\n\n          -  Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1\n\n          -  no prior chemotherapy or radiotherapy\n\n          -  adequate bone marrow, hepatic and renal function (absolute neutrophil count [ANC] \u2265\n             1.5\u2179109/L, platelet count \u2265 100\u2179109/L, total bilirubin \u2264 1.5\u2179upper limit of normal\n             [ULN], serum transaminases \u2264 2.5\u2179ULN, alkaline phosphatase \u2264 2.5\u2179ULN, serum\n             creatinine \u2264 1.5\u2179ULN or actual or calculated creatinine clearance \u2265 50 mL/min).\n\n        Exclusion Criteria:\n\n          -  clinical stage T1 tumors\n\n          -  clinical or radiologic evidence of distant metastasis\n\n          -  intestinal obstruction or impending obstruction\n\n          -  active tumor bleeding\n\n          -  interstitial pneumonitis or symptomatic pulmonary fibrosis\n\n          -  peripheral neuropathy of National Cancer Institute Common Toxicity Criteria (NCI-CTC)\n             grade \u22651\n\n          -  pregnant or breastfeeding patients\n\n          -  other serious diseases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01851941", 
            "org_study_id": "H 0406127 007", 
            "secondary_id": "H 0406127 007"
        }, 
        "intervention": {
            "arm_group_label": "mFOLFOX6", 
            "description": "Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.", 
            "intervention_name": "mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Leucovorin", 
                "Folic Acid", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "other_outcome": [
            {
                "measure": "gene expression profile", 
                "safety_issue": "No", 
                "time_frame": "after 4 cycles of chemotherapy (expected average of 8 weeks)"
            }, 
            {
                "measure": "early metabolic response by PET-CT", 
                "safety_issue": "No", 
                "time_frame": "2 cycles of chemotherapy (expected average of 4 weeks)"
            }, 
            {
                "measure": "Pharmacologic Genetic Marker", 
                "safety_issue": "No", 
                "time_frame": "4 cycles of chemotherapy (expected average of 8 weeks)"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "clinical response rate as assessed using RECIST criteria, with computed tomography (CT) scans at baseline and after 4cycles of chemotherapy", 
            "safety_issue": "No", 
            "time_frame": "4 cycles of chemotherapy (expected average of 8 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01851941"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Seock-Ah Im", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "From date of study enrollment until the date of first documented progression, assessed up to 60 months"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "From date of study enrollment until the date of first documented progression, assessed up to 60 months"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2004", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}